纤溶酶原激活剂

野生型组织型纤溶酶原激活剂（t-PA）工程细胞株生物学特性分析

The analysis of biological characteristics for the wild-type t-PA engineering cell lines

急性白血病血浆组织纤溶酶原激活剂及其抑制剂活性的测定

Clinical significance of determination of t-PA and Pai activity in plasma of patients with acute leukemia

定量检测组织型纤溶酶原激活剂夹心ELISA方法的建立

Establishment of a Sandwich ELISA for Quantitative Measurement of Tissue-type Plasminogen Activator

RT-PCR检测胃癌组织中尿激酶型纤溶酶原激活剂mRNA水平表达

Expression of Urokinase-type Plasminogen Activator mRNA in Gastric Cancer Tissues

血尿激酶型纤溶酶原激活剂mRNA水平表达与乳腺癌及其淋巴结转移的关系

Study on Relationship Between mRNA of Urokinase-Type Plasminogen Activator and Breast Cancer , Lymph Nodes Metastasis

RT-PCR测定组织纤溶酶原激活剂突变体（La-tPA）在转基因鼠乳腺表达的研究

La tRA Expression Determination by RT PCR in Mammary Gland of Transgenic Mice

关节盘前移位对关节滑膜尿激酶型纤溶酶原激活剂及其1型抑制剂mRNA表达的影响

Effect of Disc Displacement on mRNA Expression of Urokinase Plasminogen Activator and Its Inhibitor - 1 in Synovial Tissues

EGF对小鼠角质形成细胞中组织型纤溶酶原激活剂表达的调节

Regulation of tissue plasminogen activator expression by EGF in epidermal keratinocytes of mouse

MCF-7细胞中组织型纤溶酶原激活剂乳腺特异性表达载体的瞬时表达

Transient expression of tissue-type plasminogen activator in mammary carcinoma cell line MCF-7

组织型纤溶酶原激活剂（t-PA）及其突变体的表达研究进展

Progresses in the Expression of Tissue-Type Plasminogen Activator and Its Mutants

组织型纤溶酶原激活剂（t-PA）、纤溶酶原激活剂抑制剂（PAI）均是体内纤溶系统的重要组成部分。

PAI and t-PA are important constituents of fibrinolytic system in human body .

载脂蛋白AI、组织型纤溶酶原激活剂显著低于对照组（P＜0.001和P＜0.01）。

The concentration of Apo A I and t PA activity were obviously lower than those of the controls ( p < 0 001 and 0 01 , respectively ) .

尿激酶型纤溶酶原激活剂（uPA）系统在子宫内膜癌中的研究进展

Study On uPA System in the Carcinoma of Endometrium

抗PAI抑制作用的组织纤溶酶原激活剂在大肠杆菌中的表达

Expression and activity of tissue-type plasminogen activator mutant reteplase with deletion of PAI-1 binding sites

组织型纤溶酶原激活剂&膜联蛋白A5融合基因的构建

Construction of Tissue Plasminogen Activator-annexin A5 Fusion Gene

组织型纤溶酶原激活剂（t-PA）对实验性青光眼滤过性手术瘢痕形成的影响

Effects of tissue plasminogen activator ( t-PA ) on scar formation after experimental filtration surgery

采用尿激酶（75万~150万U）或重组组织型纤溶酶原激活剂（50~100mg）溶栓。

Urokinase ( 750 ? 000 U-1 ? 500 ? 000 U ) and recombinant tissue-type plasminogen activator ( 50-100 mg ) were administered as thrombolytic agents .

本文建立了组织型纤溶酶原激活剂（t-PA）活力的发光固相测定方法。

A luminescence solid phase assay for tissue type plasminogen activator ( t-PA ) was developed .

目的研究兔角膜碱烧伤后修复过程中，组织型纤溶酶原激活剂（tPA）和2型纤溶酶原激活剂抑制剂（PAI2）的作用。

Objective To explore the function of tPA and PAI-2 in the course of corneal repair after alkali burn .

单链尿激酶型纤溶酶原激活剂Kringle结构域催化功能探讨

Catalysis-related Function of Kringle Domain of Single Chain Urokinase-type Plasminogen Activator

本文用尿激酶（UK）和人体组织型纤溶酶原激活剂（t-PA）进行了兔髂股动脉血栓实验性溶解的对照研究。

The thrombolytic effect was compared between urokinase ( UK ) and human tissue plasminogen activator ( t-PA ) in rabbits with experimental iliofemoral artery thrombus .

采用发色底物分析法检测血浆组织型纤溶酶原激活剂（t－PA）及其抑制物（PAI）的活性及P／t比值。

Chromogenic peptide substrate analytical method was used to detect plasma tissue plasminogen activator ( t-PA ), tissue plasminogen activator inhibitor ( PAI ) activity and ratio of P / t.

用不同浓度儿茶酚胺灌流大鼠下肢血管床，观察它们对血管内皮细胞释放纤溶酶原激活剂（PA）的作用。

The present study , using the different catecholamines , observed the effects on plasminogen activator ( PA ) activity release in the vascular wall of rat hindlegs .

目的比较小剂量重组组织型纤溶酶原激活剂（rtPA）与直接冠状动脉（冠脉）支架术治疗急性心肌梗死（AMI）的临床疗效。

Objective To compare the efficacy of low dose recombinant tissue-type plasminogen activator ( rt-PA ) thrombolysis with primary coronary stenting after acute myocardial infarction ( AMI ) .

微血管病变组、大血管病变组的纤溶酶原激活剂抑制物、组织型纤溶酶原激活剂、和纤维蛋白原高于对照组（P0.01）。

The serum levels of plasminogen activator inhibitor-1 , tissue plasminogen activator and fibrinogen were significantly increased in MI , MA groups ( P0.01 ) than those in controls .

尿型纤溶酶原激活剂（uPA）是新一代的基因工程溶栓药物。

Recombinant human glycosylated urinary type plasminogen activator ( u-PA ) is a new generation of thrombolysis agent of genetic engineering .

目的探讨组织型纤溶酶原激活剂（tPA）参与人表皮角质形成细胞（KC）分化调控的作用。

Objective To explore the regulating roles of tissue-type plasminogen activator ( tPA ) in the differentiation of keratinocyte in the human epidermis .

血浆纤溶酶原激活剂抑制物1（PAI-1）是由多种细胞分泌的糖化蛋白，在体内参与多种生理过程。

Plasminogen activator inhibitor-1 ( PAI-1 ) is a single-chain glycoprotein secreted by many kinds of cells , which participates in many physiological process .

被感染的受体细胞NIH3T3高效表达具有纤溶活性的重组人组织型纤溶酶原激活剂。

The expression oft-PA was demonstrated in the NIH3T3 cells infected with the recombinant virus .

人纤溶酶原激活剂抑制物2型（PAI-2）在大肠杆菌中的表达和分离纯化

Expression and Purification of Human Plasminogen Activator Inhibitor Type 2 in E.coli